Homology Medicines Inc reports results for the quarter ended in June - Earnings Summary

Q32 Bio

15/08/2022 22:17

* Homology Medicines Inc  FIXX.OQ  reported a quarterly
adjusted
loss of 51 cents​​ per share for the quarter ended in June. The
mean expectation of ten analysts for the quarter was for a loss
of 56 cents per share.
    * Revenue fell 63.3% to $802.00 thousand from a year ago;
analysts
expected $1.00 million. 
    * Homology Medicines Inc's reported EPS for the quarter was
a loss
of 51 cents​.
    * The mean earnings estimate of analysts had fallen by
about 1.2%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Homology Medicines Inc shares had risen by 40.1% this
quarter and lost 24.2% so far this year.
    * The company reported a quarterly loss of $29.09 million.
    * Wall Street's median 12-month price target for Homology
Medicines Inc is $9.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 15
at 09:17 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.56          -0.51          Beat
 Mar. 31 2022      -0.35          -0.20          Beat
 Dec. 31 2021      -0.59          -0.59          Met
 Sep. 30 2021      -0.60          -0.54          Beat